Nicox SA (OTCMKTS:NICXF – Free Report) – Equities research analysts at HC Wainwright lifted their Q2 2027 EPS estimates for Nicox in a research report issued to clients and investors on Wednesday, September 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.10 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for Nicox’s current full-year earnings is ($0.08) per share.
Nicox Price Performance
Shares of OTCMKTS NICXF opened at $0.30 on Thursday. The stock has a fifty day moving average price of $0.30 and a 200 day moving average price of $0.30. Nicox has a 1-year low of $0.25 and a 1-year high of $0.30.
About Nicox
Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.
The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.
Further Reading
- Five stocks we like better than Nicox
- Enova’s Earnings Surge Meets a Valuation Test
- SLB’s Kelvion Deal Could Change How Investors Value the Oilfield Giant
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
